Entellus Medical, Inc. (ENTL) Raised to “Buy” at BidaskClub
BidaskClub upgraded shares of Entellus Medical, Inc. (NASDAQ:ENTL) from a hold rating to a buy rating in a research report released on Saturday.
A number of other brokerages also recently commented on ENTL. Zacks Investment Research upgraded Entellus Medical from a sell rating to a hold rating in a report on Tuesday, August 1st. Piper Jaffray Companies restated a buy rating on shares of Entellus Medical in a report on Wednesday, July 12th. Canaccord Genuity downgraded Entellus Medical from a buy rating to a hold rating and decreased their target price for the company from $22.00 to $18.00 in a report on Thursday, May 4th. ValuEngine upgraded Entellus Medical from a strong sell rating to a sell rating in a report on Friday, June 2nd. Finally, William Blair restated an outperform rating on shares of Entellus Medical in a report on Wednesday, May 10th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. Entellus Medical currently has a consensus rating of Hold and a consensus price target of $21.83.
Shares of Entellus Medical (NASDAQ:ENTL) opened at 17.34 on Friday. The company’s market cap is $439.93 million. The stock has a 50 day moving average of $17.16 and a 200 day moving average of $14.93. Entellus Medical has a 1-year low of $11.47 and a 1-year high of $22.63.
Entellus Medical (NASDAQ:ENTL) last announced its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.03. The business had revenue of $22.10 million for the quarter, compared to the consensus estimate of $21.87 million. Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. Entellus Medical’s revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.27) EPS. Analysts predict that Entellus Medical will post ($1.62) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://theolympiareport.com/2017/08/22/entellus-medical-inc-entl-raised-to-buy-at-bidaskclub.html.
Institutional investors have recently bought and sold shares of the company. Kopp Investment Advisors LLC increased its position in Entellus Medical by 0.5% in the second quarter. Kopp Investment Advisors LLC now owns 11,874 shares of the medical technology company’s stock worth $197,000 after buying an additional 55 shares during the period. Parametric Portfolio Associates LLC increased its position in Entellus Medical by 5.6% in the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock worth $150,000 after buying an additional 573 shares during the period. First Mercantile Trust Co. increased its position in Entellus Medical by 45.3% in the second quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock worth $136,000 after buying an additional 2,557 shares during the period. Bank of America Corp DE increased its position in Entellus Medical by 53.8% in the first quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock worth $102,000 after buying an additional 2,594 shares during the period. Finally, Nationwide Fund Advisors increased its position in Entellus Medical by 61.7% in the second quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock worth $114,000 after buying an additional 2,635 shares during the period. Institutional investors and hedge funds own 67.61% of the company’s stock.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.